Search PubMed⌕ Search

Biomedical subjects

F Halter

Publications and source records attributed to F Halter.

At least 181 records · Page 10Linked to original sources
PubMed1975

[Indications for and effectiveness of retrograde cholangiopancreatography].

The practical value of endoscopic retrograde cholangiopancreatography (ERCP) has been evaluated on the basis of experience in 159 own examinations. The cannulation rate as an important index of the success rate rose with experience, and was 85 percent in the last 110 cases. Diagnostic information was however obtained only in 65 percent, as it was not always possible to cannulate the appropriate ductule system and differentiation between chronic inflammatory and neoplastic pancreatic disease was often difficult. The greatest reliability was found in bilary duct disease, though the difference as compared with pancreatic disease was not significant. With strict limitation of the indication and a few important precautions (avoiding parenchymography of the pancreas and prompt surgical drainage of an obstructed biliary duct or pancreatic pseudocysts) no severe complications were observed throughout this series. The morbidity was thus limited to 4 cases of pancreatitis of moderate severity. In spite of the limitations of ERCP in differentiating malignant from chronic inflammatory pancreatic disease, the method was valuable for establishing the indication for, and planning, surgery. Furthermore, the diagnostic reliability was improved by combining ERCP with selective pancreatic angiography.

Cholangiography↗
PubMed1975

[Selective pancreatic angiography and retrograde pancreatic cholangiography as a combined examination].

The diagnostic value of selective pancreatic angiography and retrograde pancreatic cholangiography used in combination was studied in 24 patients with chronic pancreatitis or pancreatico-duodenal carcinomas. This was done as a prospective study. The accuracy of the individual methods is 75% and 79% respectively; used in combination, a correct diagnosis is obtained in 91% of cases. The advantage of combining the techniques depends on the fact that they supplement each other.

Adenoma, Bile Duct↗
PubMed1975

Secretin snuff: evaluation of the action on pentagastrin-stimulated gastric acid secretion and on pancreatic bicarbonate production.

In an informative qualitative study 75 U (near the range of 1 U/kg) secretin given as a snuff resulted in a weak but significant stimulation of pancreatic bicarbonate output in 8 volunteers studied. The result further indicated that this dose would slightly inhibit pentagastrin-stimulated gastric acid secretion. This was confirmed in a quantitative study at the dose of 150 U (similar to 2 U/kg), and the mean amount of inhibition of MAO was 30% in the 10 subjects studied. A supramaximal dose of 1 mg (approximatively 54 U/kg) of synthetic secretin given to one volunteer resulted in a transient block of near maximally pentagastrin-stimulated gastric acid secretion. The amount of acid inhibition as compared to a control experiment was 45% in the first and 52% in the two post-secretin hours. These results indicate that secretin given as a snuff at dose levels that would induce maximal pancreatic secretion when given as an i.v. injection results only in a weak inhibition of stimulated gastric acid secretion and evokes only a little stimulation of pancreatic bicarbonate secretion. Supramaximal secretin snuff doses have, however, a potent effect on both gastric and pancreatic secretion that is of similar order to that achieved by intravenous secretin. Owing to the obviously incomplete absorption of secretin through the nasal mucosa, secretin snuff is unlikely to solve the therapeutic problem of duodenal ulcer disease. If, however, an active fragment of the peptide could be synthetized at a reasonable price, the greater convenience of pernasal application might compensate for the partial loss of action.

Adult↗